GLP1 receptor (GLP1R)

Our GLP1R fluorescent ligands have been tested extensively in a range of cell lines and have been found to be highly specific for the GLP-1 receptor. They are ideal for studying the GLP1 receptor in various contexts, including the study of type 2 diabetes, weight loss, and kidney disease. As a market leader in fluorescent ligand development, we are uniquely positioned to supply high-quality GLP1R solutions with high affinity for the GLP-1 receptor, making them ideal for various applications, including live cell imaging, receptor activation assays, and more.

LUXendins have been developed by Johannes Broichhagen (Max Planck Institute for Medical Research, Heidelberg, Germany and Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany) and David J. Hodson (University of Birmingham), and are exclusively licensed to Celtarys for commercialization. These ligands have been shown to be highly effective in studying the GLP-1 receptor and related proteins, including glucagon-like peptide and GLP-1 receptor agonists. The ligands are also highly effective in studying the nervous system, blood sugar levels, and cell surface signaling pathways. They have been shown to be highly effective in binding to the receptor, activating it, and studying its downstream effects.

At Celtarys, we are committed to providing you with the best products on the market for studying G protein-coupled receptors, and we are constantly developing new solutions to meet your needs.